| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | GXII; ROSSY; PLA2G12 |
| Entrez GeneID | 81579 |
| clone | 3H2C11 |
| WB Predicted band size | 21kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PLA2G12A (AA: 21-189) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于PLA2G12A抗体的3篇参考文献示例(内容为模拟生成，仅供参考)：
1. **"PLA2G12A regulates hepatitis C virus replication by modulating lipoprotein secretion"**
*作者：Smith A, et al. (2020), Journal of Virology*
**摘要**：研究利用PLA2G12A特异性抗体发现，该酶通过影响肝细胞脂蛋白分泌通路，间接调控HCV病毒颗粒的组装和释放。
2. **"A novel monoclonal antibody reveals PLA2G12A expression in atherosclerotic plaques"**
*作者：Chen L, et al. (2018), Arteriosclerosis Research*
**摘要**：开发了一种高特异性抗人PLA2G12A单克隆抗体，证实其在动脉粥样硬化斑块中的巨噬细胞高表达，提示其可能参与炎症反应和脂质代谢异常。
3. **"PLA2G12A deficiency alters phospholipid metabolism: Insights from antibody-based knockout validation"**
*作者：Yamamoto K, et al. (2021), Biochimica et Biophysica Acta (BBA)-Molecular Cell Biology*
**摘要**：通过抗体介导的蛋白敲低技术，发现PLA2G12A缺失会导致细胞膜磷脂组成改变，影响脂质信号传导通路。
4. **"Antibody profiling identifies PLA2G12A as a biomarker for metabolic syndrome"**
*作者：Wang X, et al. (2019), Clinical Chemistry*
**摘要**：采用PLA2G12A多克隆抗体进行血清蛋白组学分析，发现其水平与胰岛素抵抗和血脂异常显著相关，提示其作为代谢综合征潜在生物标志物的价值。
(注：以上文献信息为基于领域知识的模拟生成，实际引用需以真实出版物为准。)
PLA2G12A (Phospholipase A2 Group XIIA) is a member of the phospholipase A2 superfamily, enzymes that hydrolyze phospholipids to release fatty acids and lysophospholipids. Unlike secreted or cytosolic PLA2s, PLA2G12A is classified as a "group XII" enzyme with atypical catalytic properties. It is primarily expressed in the liver and endothelial cells, playing roles in lipoprotein metabolism and vascular homeostasis. Studies suggest its involvement in regulating very-low-density lipoprotein (VLDL) secretion and maintaining plasma lipid profiles.
Antibodies targeting PLA2G12A have emerged as critical tools for investigating its biological functions and pathological associations. These antibodies enable the detection of PLA2G12A expression in tissues, quantification of protein levels, and exploration of its interactions in lipid metabolism pathways. Research has linked PLA2G12A dysfunction to metabolic disorders, including hypertriglyceridemia and atherosclerosis, as well as inflammatory conditions. Recent work also implicates PLA2G12A in viral infections, such as hepatitis C virus replication, highlighting its broader biomedical relevance.
Commercial PLA2G12A antibodies are typically developed in rabbits or mice using immunogenic peptide sequences. Validation often includes Western blotting, immunohistochemistry, and knockout controls to confirm specificity. Ongoing studies aim to clarify its catalytic mechanisms and therapeutic potential, making PLA2G12A antibodies essential for both basic research and translational applications in cardiometabolic and infectious diseases.
×
